INCPF Stock - InnoCare Pharma Limited
Unlock GoAI Insights for INCPF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.01B | $738.54M | $625.40M | $1.04B | $1.36M |
| Gross Profit | $871.01M | $610.10M | $482.01M | $977.37M | $1.36M |
| Gross Margin | 86.3% | 82.6% | 77.1% | 93.7% | 100.0% |
| Operating Income | $-525,784,000 | $-651,154,128 | $-770,404,000 | $-181,104,000 | $-558,986,000 |
| Net Income | $-440,633,000 | $-631,263,000 | $-886,593,000 | $-64,545,000 | $-391,395,000 |
| Net Margin | -43.7% | -85.5% | -141.8% | -6.2% | -28694.6% |
| EPS | $-0.26 | $-0.37 | $-0.60 | $-0.04 | $-0.40 |
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Visit WebsiteEarnings History & Surprises
INCPFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | — | $-0.00 | — | — |
Q3 2025 | Aug 19, 2025 | — | — | — | — |
Q2 2025 | May 13, 2025 | — | $0.00 | — | — |
Q1 2025 | Mar 27, 2025 | — | — | — | — |
Q4 2024 | Nov 11, 2024 | — | $-0.00 | — | — |
Q3 2024 | Aug 20, 2024 | — | $-0.01 | — | — |
Q2 2024 | May 13, 2024 | — | $-0.01 | — | — |
Q4 2023 | Dec 30, 2023 | — | $-0.01 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.01 | — | — |
Q2 2023 | Jun 30, 2023 | $-0.03 | $-0.03 | -16.3% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q3 2022 | Sep 30, 2022 | $-0.01 | $-0.03 | -146.3% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | — | $-0.04 | — | — |
Q1 2022 | Mar 22, 2022 | $0.06 | $0.02 | -74.4% | ✗ MISS |
Q3 2021 | Sep 29, 2021 | — | $0.03 | — | — |
Q3 2021 | Aug 27, 2021 | $-0.03 | $-0.02 | +11.1% | ✓ BEAT |
Q1 2021 | Mar 26, 2021 | $-0.03 | $-0.01 | +76.2% | ✓ BEAT |
Q1 2021 | Mar 26, 2021 | $-0.03 | $-0.01 | +76.2% | ✓ BEAT |
Q4 2019 | Dec 31, 2019 | — | $-0.17 | — | — |
Frequently Asked Questions about INCPF
What is INCPF's current stock price?
What is the analyst price target for INCPF?
What sector is InnoCare Pharma Limited in?
What is INCPF's market cap?
Does INCPF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to INCPF for comparison